Alterity Therapeutics annual r&d spending
2016
2017
2018
2019
2020
2021
2022
2023
2024
2025
2026
Alterity Therapeutics R&D Spending Growth & History (ATHE)
Alterity Therapeutics's r&d spending was $17.6M for fiscal 2026.
View full Alterity Therapeutics company overviewAlterity Therapeutics annual r&d spending history
| Fiscal year | Period ended | R&D spending | Change | Growth |
|---|---|---|---|---|
| 2026 | 2026-06-30 | $17.6M | $3.2M | +22.39% |
| 2025 | 2025-06-30 | $14.4M | −$4.2M | −22.74% |
| 2024 | 2024-06-30 | $18.6M | $5.4M | +41.26% |
| 2023 | 2023-06-30 | $13.2M | −$1.5M | −10.49% |
| 2022 | 2022-06-30 | $14.7M | $2.5M | +20.04% |
| 2021 | 2021-06-30 | $12.3M | $2.2M | +21.64% |
| 2020 | 2020-06-30 | $10.1M | −$2.9M | −22.22% |
| 2019 | 2019-06-30 | $13.0M | $6.3M | +93.84% |
| 2018 | 2018-06-30 | $6.7M | $997,677 | +17.50% |
| 2017 | 2017-06-30 | $5.7M | −$3.9M | −40.53% |
| 2016 | 2016-06-30 | $9.6M | — | — |
Alterity Therapeutics r&d spending trends
Over the last five fiscal years, Alterity Therapeutics's r&d spending increased from $12.3M to $17.6M, a change of $5.3M.
About the metric
What research and development spending means
Research and development (R&D) spending covers the costs of creating and improving products, services, software, technologies, and processes. Higher R&D spending may support future innovation, but the amount alone does not show whether those investments will generate returns.
Calculation and source
SEC-reported R&D expense
TickerStat standardizes research and development expense reported in company SEC filings, including the software-specific US-GAAP R&D concept when it is the filer’s primary R&D expense line. It is historical company-reported spending, not an estimate or forecast. Fiscal periods can differ from calendar years, so exact period-end dates are included.
Review Alterity Therapeutics source filings ↗